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Tropenol ester is a highly toxic anticholinergic substance and an intermediate used in industrial production of the 
bronchodilator tiotropium bromide. The aim of this study was to systematically test workers involved in its production 
for tropenol ester in urine to identify any exposure pathways and define additional preventive measures. Twelve workers 
performing tasks involving potential exposure to tropenol ester were repeatedly monitored at the end of each production 
cycle. Medical exams revealed no symptoms of acute poisoning with tropenol ester, but biological monitoring of urine 
showed 36 positive findings in 79 samples, with tropenol ester concentrations ranging between the detection limit of 
54 pg/mL and 2160 pg/mL. We managed to establish the cause of only one positive finding, which was a hole in a protective 
glove, whereas the rest most likely occurred due to human error. Because of this, the plant decided to modify the production 
process by replacing tropenol ester with a safer intermediate. While it is the safest course of action, there where it cannot 
be taken, biological monitoring can be very helpful in raising awareness about exposure to toxic substances, including 
the new ones that have not been studied for their adverse potential.
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Industrial innovations – whether they involve new 
technologies or new chemical substances – inevitably raise 
issues about occupational safety during their development 
and production (1–3) despite sophisticated safety measures 
and intensive training of employees.
One such chemical substance is tropenol ester [di-(2-
thienyl)glycolic acid tropenol ester] (4), a precursor of the 
bronchodilator tiotropium bromide (5). Tropenol ester is 
readily absorbed through the skin, binds to muscarinic 
acetylcholine receptors, and has an exceptionally high 
receptor affinity (4). In 2012, we reported a case of tropenol 
ester poisoning with severe anticholinergic symptoms that 
lasted unusually long – two weeks. Fortunately, they were 
completely reversible. Earlier, in 1994, we reported work-
related poisoning with another anticholinergic intermediate 
used in the synthesis of tiotropium bromide, i.e. scopine 
ester [scopine di-(2-thienyl)glycolate] (6, 7). After the acute 
anticholinergic symptoms had subsided, symptoms of a 
newly developed encephalopathy became apparent and did 
not improve over the next eight years of follow-up. 
Repeated thorough medical examinations did not provide 
evidence of any non-occupational cause of encephalopathy 
(personal observation). In contrast to FDA-approved 
tiotropium bromide, both of these intermediates used in its 
synthesis can quickly pass the blood-brain barrier as tertiary 
amines, have high receptor activity, and are readily absorbed 
through the skin, which explains their severe toxic action 
(4, 6).
The case of tropenol ester poisoning came as a surprise 
to all involved and triggered a detailed review of all 
precautionary measures in the company. Apparently, all 
precautions had been taken to prevent occupational 
exposure. Production was not continuous but was carried 
out in cycles lasting two weeks. The equipment used for 
production was set up for each cycle and cleaned after 
production was completed. The only anticholinergic 
intermediates used were tropenol ester and scopine ester. 
The workers were potentially exposed to tropenol ester 
throughout the shift, especially when shovelling dry powder 
from/into reaction vessels, taking samples for analysis, 
cleaning equipment, and taking off protective clothing. 
These operations cumulatively lasted about one hour per 
shift. Scopine ester was used as a solution in a closed 
system. Each worker basically carried out all activities. 
There was no rotation schedule. During the last production 
cycle, only particularly experienced employees shovelled 
tropenol ester. Employees wore chemical-resistant boots, 
protective suits, gloves, and full masks with P3 filters for 
all activities. Protective gloves were made of butyl or nitrile. 
The manufacturer had tested their permeability with a 
powder of tropenol ester and found none over the 480 
minutes of the test. The wearing times during operation 
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were considerably shorter. Gloves were changed after each 
activity involving exposure to tropenol ester. In addition, 
new gloves were used at the beginning of each shift. The 
scalp and the skin on the neck was completely covered. 
Employees wore overshoes over their boots. The overshoes 
were attached to the protective suit with adhesive tape to 
prevent contamination of the employees’ work boots. After 
each operation involving potential exposure, the protective 
clothing and gloves were first decontaminated and only then 
removed and disposed of. There were changing rooms with 
separate storage options for work and street clothes. The 
employees showered after work. The concentration of 
tropenol ester in the air was never measured because 
measurement would have had no practical purpose for 
occupational safety. Exposure could only occur during 
cleaning of the equipment and removal of protective 
clothing. Yet, no systematic deficits were found. The most 
likely cause of acute poisoning was human error (4).
Since human error can never be prevented with certainty 
and both intermediate products are highly toxic, intensified 
efforts were made to improve occupational safety by 
introducing urine biomonitoring for tropenol ester as the 
least inconvenient sampling method for the workers. The 
detection of an intermediate product in workers’ urine was 
intended as a red flag that would launch an investigation 
into possible exposure pathways. To implement this 
practical approach as quickly as possible, we skipped a full 
validation (8) and focused on detection rather than reliable 
quantification of internal exposure. What follows is a report 
on our findings and steps taken to improve the implemented 
occupational safety measures, including biological 
monitoring.
PARTICIPANTS AND METHODS
Participants and medical advice
The company physician informed the workers about the 
required industrial hygiene and possible symptoms of 
poisoning with an anticholinergic compound in detail. In 
the event of symptoms or potential exposure, the workers 
were instructed to immediately refer to the company 
medical office, which was staffed around the clock. They 
were also invited to take additional preventive measures, 
i.e. medical check-ups and biological monitoring and all 
12 of them responding willingly, aware of the risks of 
tropenol ester poisoning. Good communication is essential 
in this respect (9). At the time of the first check-up, the 
median age of the 12 men was 26 years (range 21–43). One 
worker left the department after the second production cycle 
for personal reasons not related to potential exposure. He 
was not replaced.
Biological monitoring
For practical reasons, the workers gave a urine sample 
at the end of each production cycle. Perceived exposure to 
an anticholinergic compound was not reported. Therefore, 
no additional inquiries about perceived exposure were 
necessary.
Urine samples were also taken from 12 participants 
unexposed to anticholinergics for method validation. The 
samples were collected in vessels containing 10 mL of citric 
acid (1 mol/L) for stabilisation. Ten-millilitre aliquots of 
the acidified samples were stored at -20 °C until analysis. 
Tropenol ester in urine was determined with a modified 
liquid chromatography – tandem-mass spectrometry 
(HPLC-MS/MS) method for rat plasma developed by the 
pharmaceutical manufacturer. After pH adjustment with 
sodium hydroxide, the urine samples were extracted by 
liquid-liquid extraction with methyl tert-butyl ether and the 
extracts analysed for two ion transitions: 362.1>122.0 and 
362.1>140.1. The chromatograph was calibrated by external 
calibration with internal standard correction. Each sample 
was analysed in duplicate, quantifying concentrations for 
both ion transitions. Urinary analyte concentrations were 
reported as mean values of the duplicate analyses and 
concentration calculations. No exhaustive validation data 
are available for the described analytical method, but 
repeatability and accuracy were ensured by repeated 
analyses of quality control samples spiked with three known 
concentrations of tropenol ester [low (272 pg/mL), medium 
(1090 pg/mL), and high (5440 pg/mL)] in each analytical 
series (n=6 for each concentration). The coefficients of 
variation as a measure of inter assay-repeatability were 
12.9 % at low concentration and ion transition 362.1>140.1 
but <7 % for all other concentrations and transitions. 
Relative recovery as a measure of the method’s accuracy 
was between 96.5 % and 103.6 % for all concentration 
levels and both ion transitions. The method’s lower limit 
of quantification (LLOQ) was 54 pg per mL of urine. The 
detection limit was also 54 pg/mL. Since the main goal of 
our investigation was to detect internal exposure, we made 
no further adjustment of the urinary tropenol ester 




None of the employees described any physical 
discomforts at any point during any of the examinations. 
None of them experienced any symptoms or clinical signs 
suggesting adverse effects of exposure to an anticholinergic 
compound such as dry mouth, thirst, fixed and dilated 
pupils, flushed face, fever, hot, dry, and red skin, 
tachycardia, impaired speech, blurred vision, swallowing, 
or impaired motor activity or coordination (4, 10).
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Exposure
None of the employees reported any perceived exposure 
to anticholinergic compounds. Table 1 shows the urine 
concentrations of tropenol ester for each participant after 
completion of each production cycle. The highest 
concentration found was 2160 pg/mL. In 36 of 79 
measurements, the concentrations were above the detection 
limit of 54 pg/mL. Positive urine samples triggered in-depth 
investigation. The first two authors thoroughly checked all 
personal protective equipment and found a hole in the 
protective glove of the participant no. 12, who was 
measured 1340 pg of tropenol ester per mL of urine at the 
end of the first production cycle. No other causes were found 
that could explain other positive samples.
DISCUSSION
With additional precautionary measures taken in our 
study, not even a mild poisoning was established. However, 
we were surprised by positive urine findings for tropenol 
ester in almost half of the samples, and only in one case it 
could reasonably be associated with a hole in a protective 
glove. In this context, it is worth noting that tropenol ester 
was processed as powder. No solvents were used that could 
have damaged protective gloves or clothing.
In retrospect, it is not possible to associate individual 
urine concentrations with specific activities. That no 
concrete cause of internal exposure was established for the 
35 positive samples is unsatisfactory from the point of view 
of occupational safety, regardless of the absence of 
poisoning symptoms in any of the workers. We can only 
speculate about possible exposure routes. Since tropenol 
ester is easily absorbed by the skin, and respiratory 
protection was continuously worn, the most likely route 
was skin. Even a minor negligence in occupational hygiene 
can lead to dermal absorption (4, 11). This points to a human 
error, which may have occurred during removal of 
protective clothing, but there was no evidence to confirm 
the assumption. After the first production cycle, tropenol 
ester was detected in 11 of 12 samples, and after the last 
cycle only in 1 of 11 (Table 1). Perhaps the awareness of 
the results of biological monitoring contributed to better 
personal occupational hygiene. However, experience shows 
that necessary protective measures are not always followed, 
even if the risks are known (12).
Interpretation of our findings would benefit greatly from 
the knowledge about the toxicokinetics of tropenol ester 
(13), but there is none. This is the major limitation of our 
investigation, as, without this information, the choice of 
sample (urine) and the timing of collection relied on 
practical reasons. Furthermore, there are no limit values for 
tropenol ester in urine or other biological material that can 
be used to evaluate the measured concentrations. What we 
do know, however, is that all of our participants were 
symptom-free, even if their samples showed traces of 
tropenol ester. Our earlier case report (4) gives an indication 
of the level that can be associated with poisoning (4). 
Namely, we later measured the concentration of tropenol 
ester in the remaining urine sample of the poisoned patient 
taken between two and five hours after reported exposure. 
It was 0.5 mg tropenol ester/L urine, that is, more than 200 
times higher than the highest concentration measured in 
this study (2160 pg/mL, Table 1).
Clearly, tropenol ester concentrations established in our 
study did not cause acute toxicity in healthy individuals. 
However, persons who are more sensitive due to illness, 
e.g. narrow-angle glaucoma, could be more susceptible to 
anticholinergics, and would have to avoid every risk of 
exposure. The company physician had made sure that none 
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Table 1 Concentrations of tropenol ester in urine (pg/mL) and percentage of positive samples per production cycle 
Production cycle 1 2 3 4 5 6 7
Worker
1 2160 500 75 250 <LOD <LOD <LOD
2 605 130 <LOD <LOD <LOD <LOD <LOD
3 365 170 <LOD <LOD 83 395 140
4 60 70 <LOD 115 <LOD <LOD <LOD
5 1390 170 125 150 415 145 <LOD
6 <LOD <LOD <LOD <LOD <LOD <LOD <LOD
7 100 <LOD * * * * *
8 300 <LOD 420 <LOD <LOD <LOD <LOD
9 180 75 <LOD 710 <LOD 120 <LOD
10 180 <LOD 365 1530 <LOD <LOD <LOD
11 210 200 <LOD <LOD <LOD <LOD <LOD
12 1340 350 <LOD 175 <LOD 250 <LOD
All subjects, % ≥ 
LOD 91.7 66.7 36.4 54.5 18.2 36.4 9.1
Samples were taken at the end of each production cycle (1–7); * worker left production; LOD – limit of detection, 54 pg/mL
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of the employees in his care had any of these illnesses. We, 
however, did not look for possible immunomodulatory 
effects. Acetylcholine receptors including the muscarinic 
ones are also expressed by epithelial, mesothelial, and 
immune cells (14, 15). Recent findings suggest that the 
immune function can be modulated by manipulating 
immune-cell cholinergic activity with specific agonists and 
antagonists (15). Perhaps a future research should 
investigate whether occupational exposure to tropenol ester 
could actually have an immunomodulatory effect.
In the meanwhile, tropenol and scopine ester were 
excluded from the production process as intermediates to 
prevent any exposure and thus acute poisoning and 
unknown immunomodulatory effects. Judging by internet 
search results showing that a number of plants worldwide 
still use scopine and tropenol ester to produce tiotropium 
bromide, it is quite conceivable that their workers are at 
risk of exposure. In this case, prevention of the kind 
described above is indicated.
In conclusion, although tropenol ester is now rarely 
used, the basic principle of exposure prevention and 
biomonitoring can be applied to other newly developed 
substances, their precursors, and by-products of synthesis 
reactions. Even at the development stage and without 
established risk thresholds, these substances or their 
intermediate products should be investigated for toxicity 
and preventive measures considered based on this 
knowledge. Experience has shown that individual and 
systemic errors can be detected with biological monitoring. 
Positive samples can be a starting point for investigating 
exposure pathways that were previously unknown (9, 11, 
16). Subsequently, targeted occupational safety measures 
can help to minimise the risk of poisoning. However, since 
human error cannot be excluded, the best course of action 
is to replace a hazardous working substance with a non-toxic 
or at least a less dangerous substance.
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Razine tropenol estera u mokraći radnika na sintezi tiotropijeva bromida – implikacije za sprječavanje izloženosti 
i biomonitoring
Tropenol ester je iznimno toksičan antikolinergik, koji se rabi za sintezu bronhodilatatora tiotropijeva bromida. Cilj je 
ovog ispitivanja bio sustavno testirati radnike koji njime barataju u proizvodnji na tropenol ester u mokraći ne bi li se 
ustanovili putevi izloženosti i poboljšale preventivne mjere. Ispitivanje je obuhvatilo 12 radnika kroz 12 proizvodnih 
ciklusa, a uzorkovanje se provodilo na kraju svakog ciklusa. Liječničkim se pregledom nisu otkrili nikakvi simptomi 
akutnog otrovanja tropenol esterom, ali se biomonitoringom otkrilo 36 pozitivnih uzoraka od njih 79. Razine tropenol 
estera u pozitivnim uzorcima kretale su se od granice detekcije (54 pg/mL) do 2160 pg/mL. Međutim, samo smo za jedan 
pozitivan nalaz uspjeli utvrditi uzrok. Radilo se o rupi u zaštitnoj rukavici. Za ostale pozitivne uzorke pretpostavljamo 
da upućuju na ljudsku pogrešku prilikom skidanja ili čišćenja opreme. Zbog nemogućnosti da utvrdimo uzroke izloženosti, 
tvornica je promijenila proizvodni proces i tropenol ester zamijenila sigurnijim međuproizvodom. Iako je to najsigurniji 
način za sprječavanje izloženosti opasnim tvarima u proizvodnji, tamo gdje to nije moguće, biomonitoring može biti 
itekako koristan za podizanje svijesti o izloženosti, osobito kod novih tvari čije štetno djelovanje za zdravlje još nije 
istraženo.
KLJUČNE RIJEČI: analiza radnog mjesta; antikolinergici; međuproizvodi; prevencija; skopin ester
